ArticleFrontiers in medicine2025
The diagnostic and prognostic value of antithrombin III activity for sepsis-induced coagulopathy in septic patients: a prospective observational study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic Management of Septic Venous Thrombosis: A Narrative Review.Infectious disease reports · 2026Review
- Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases.Journal of intensive care · 2026Article
- Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are currently no suitable biomarkers for early diagnosis and prognostic evaluation of sepsis-induced coagulopathy ( Methods: This study is a single-center cohort study, prospectively enrolling patients with sepsis admitted to the ICU from March 2023 to March 2024. Based on whether the Results: This study included a total of 366 patients with sepsis, among which 235 (64.2%) were in the Conclusion: AT-III activity is a potentially helpful adjunctive biomarker for diagnosing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.